Semaglutide works. That question was settled by trials big enough to leave no real room for argument. “Does compounded semaglutide work” is a different question wearing the same words, because compounded semaglutide is not one product but whatever a given pharmacy happens to put in a given vial. The honest answer is that the molecule tested in those trials works, and nobody has tested what most buyers of a compounded version receive.
That gap between the tested molecule and the purchased vial drives everything that follows.
What the trials measured
Novo Nordisk’s semaglutide 2.4 mg went through a large randomized trial program before approval. In the STEP 1 trial, Wilding and colleagues randomized adults with overweight or obesity to weekly subcutaneous semaglutide 2.4 mg or placebo.[1] The result:
14.9% average body weight lost at 68 weeks on semaglutide 2.4 mg in the STEP 1 trial, versus 2.4 percent on placebo PMID 33567185
That’s a real effect. Placebo groups in trials this size don’t drift by fourteen points through chance alone. The mechanism behind it is not exotic: semaglutide is a GLP-1 receptor agonist, and the drug class works partly by slowing gastric emptying and acting directly on hypothalamic nuclei that increase satiety.[2] You feel full sooner and stay full longer, meal after meal, for as long as the drug is in your system. Nothing about that mechanism cares who manufactured the peptide, which is exactly why “does compounded semaglutide work” has a deceptively simple answer at the molecular level.
The scale of the evidence base matters too. Kushner and colleagues described the design behind that program: about 5,000 participants randomly assigned across five phase 3 trials to weekly semaglutide 2.4 mg or placebo, including a trial built specifically for people with type 2 diabetes.[3] That’s the body of trial evidence that shaped what we know about the drug, and it’s the evidence every compounded product is implicitly trying to borrow, whether or not the pharmacy selling it says so.
Every one of those trials used a manufactured, quality-controlled, single-source product. None of them used a vial from a compounding pharmacy down the street. The trial arm that got the drug and the shopper who orders from a spa’s website are, chemically, supposed to be getting the same thing. Nobody independently checked that for the second group.
What “compounded” means, and where this article hit a wall
Peptide forums and marketing copy love to draw a bright line between “real” semaglutide and the “salt forms” (semaglutide sodium, semaglutide acetate) sold by some compounders, framing the salts as an FDA-flagged bait and switch. I went looking for a citable source establishing exactly what the FDA has said about those salt forms as distinct active ingredients, and came up empty. That’s a claim this article cannot verify against the published literature, so it isn’t going to assert it as fact. Readers who have seen it stated flatly elsewhere should treat it as unconfirmed here.
What the literature does support is narrower, and arguably more useful:
Compounding rode on shortage status, never on proven equivalence. A 2026 brief report by Trainer in the Journal of the American Association of Nurse Practitioners describes how the FDA’s resolution of the semaglutide and tirzepatide shortages has narrowed the legal basis for large-scale compounding, leaving a narrow remaining role, such as for patients with a documented allergy to the approved product’s inactive ingredients.[4] Compounding was never approved as an equivalent option. It was tolerated as a stopgap.
Real people have been harmed by real compounded vials. Lambson and colleagues published a poison control case series describing three patients who received compounded semaglutide from compounding pharmacies or a medical spa.[5] Two of them self-administered tenfold dosing errors. One needed emergency evaluation for nausea, vomiting and abdominal pain, and responded to antiemetics and IV fluids.
Bottom line: the documented harm from compounded semaglutide traces back to measurement and dosing errors, the vial and the syringe, ahead of anything about the ingredient itself.
Dosing errors are the risk, not a hidden bad batch
The Lambson case series is specific about how the tenfold errors happened: patients drew doses from compounded vials that carried none of a manufactured pen’s safety features, using syringes not intended for the product, with dosing recorded in milliliters or units instead of milligrams.[5]
10x the dosing error two patients self-administered after drawing compounded semaglutide from a vial with no pen-style safety features PMID 37392810
A manufactured semaglutide pen makes that error almost impossible. It’s pre-loaded, pre-dosed, and click-counted. A vial and a syringe put the entire margin for error on the patient’s arithmetic, done at home, usually without a pharmacist standing over their shoulder.
This is an old failure mode wearing a new drug. Testosterone and human growth hormone went through the same gray-market phase decades ago: the black-market vials often did contain the labeled hormone, but concentration, sterility, and dosing accuracy were never guaranteed the way they are in a pharmaceutical manufacturing line. The lesson from that era wasn’t that the hormones themselves were fake. It was that “compounded” and “quality-controlled” are not synonyms, and the injuries showed up at the point of measurement, while the chemistry itself stayed sound.
This isn’t an isolated case series either. Gaw and colleagues tracked GLP-1 receptor agonist cases reported to United States poison centers from 2017 through 2022 and found the rate per million population climbing from 1.16 to 3.49 by 2021, then jumping another 80.9 percent to 6.32 in 2022, with most cases tied to unintentional therapeutic errors.[6]
6.32 GLP-1 agonist poison-center cases per million U.S. population in 2022, up from 1.16 in 2017 PMID 38421490
That study covers the whole GLP-1 class rather than compounded products alone, so it can’t be read as proof that compounding drove the rise by itself. But it lines up with a period when compounded access expanded fastest, and it confirms that dosing errors with these drugs happen often enough to show up in national surveillance data, which is a different order of problem than a rare fluke.
What the evidence does not establish
Nobody has run a trial. No randomized controlled trial has tested a compounded semaglutide formulation against placebo, or against the FDA-approved product, for weight-loss efficacy. Every number in the section above comes from the branded product’s own trial program.
That gap cuts both ways, and it splits into three separate points that get collapsed into one online:
It does not mean compounded semaglutide is inert. If a pharmacy compounds accurate, pure semaglutide base at the correct concentration, there is no chemical reason the STEP trial results wouldn’t extend to it. The molecule doesn’t know where it was made.
It does not mean the harm reports above represent the typical outcome. Case reports and poison-center surveillance can prove that harm happens; they cannot tell you what fraction of compounded users are harmed, because nobody is tracking the denominator.
It does mean that “compounded semaglutide works just like the real thing” is an inference rather than a finding anyone has tested. Every compounding pharmacy selling on that premise is extrapolating from someone else’s trial, on the assumption that its own vial matches the specification. Most buyers have no way to check that assumption, which is exactly the point.
Where compounded semaglutide fits for a careful buyer
If you’re weighing a compounded product anyway, the questions worth asking are the ones the evidence above points to, not the ones peptide forums argue about:
Ask what’s in the vial and get it in writing. A verbal assurance is worthless; request a certificate of analysis confirming concentration and purity.
Ask how you’re supposed to dose it. If the answer involves converting milliliters to units to milligrams on your kitchen counter, that is the exact failure mode documented above, already happening to real patients.
Ask who is teaching you to inject it. The Lambson case series is explicit that at least one patient received no pharmacist counseling at all on administration.[5] A pen comes with an instruction leaflet and a click-counter built in. A vial comes with whatever the seller decides to tell you, if anything.
Ask why you’re compounding at all. The legal room for it has narrowed since the shortage resolved, and a documented allergy to an inactive ingredient in the approved product is a real reason. Cost pressure is a real reason too, but it doesn’t come with the same safety net, and pretending otherwise is how the case reports above happen.
There’s also a comparison worth having in your back pocket. Wen and colleagues ran a meta-analysis of direct head-to-head studies comparing tirzepatide and semaglutide in people with type 2 diabetes, and found tirzepatide produced significantly greater average weight loss, about 11.4 percent versus 7.3 percent.[7]
Weight loss in head-to-head trials (type 2 diabetes)
Tirzepatide: 11.4
Semaglutide 2.4 mg: 7.3
Meta-analysis of four direct comparative studies, Wen et al 2025.
That comparison won’t settle the sourcing problem, since tirzepatide gets compounded too, and the same vial-and-syringe risks apply to it. But it’s worth knowing that semaglutide is not automatically the strongest option on the table before you decide how much sourcing risk you’re willing to accept to get it.
The molecule tested in those five trials works. Whether the one in your refrigerator is the same molecule, at the same concentration, drawn with the right syringe, is a question no trial has ever answered for you. It is the only question that determines your outcome.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
Once-Weekly Semaglutide in Adults with Overweight or Obesity.. The New England journal of medicine, 2021.
GLP-1 Receptor Agonists.. The New England journal of medicine, 2026.
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.. Obesity (Silver Spring, Md.), 2020.
The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions.. Journal of the American Association of Nurse Practitioners, 2026.
Administration errors of compounded semaglutide reported to a poison control center-Case series.. Journal of the American Pharmacists Association : JAPhA, 2023.
Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017-2022.. Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2024.
Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies.. Endocrinology, diabetes & metabolism, 2025.
